“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval
Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experienc...
Gespeichert in:
Veröffentlicht in: | The Annals of thoracic surgery 2008-11, Vol.86 (5), p.1530-1538 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1538 |
---|---|
container_issue | 5 |
container_start_page | 1530 |
container_title | The Annals of thoracic surgery |
container_volume | 86 |
creator | Hughes, G. Chad, MD Daneshmand, Mani A., MD Swaminathan, Madhav, MD Nienaber, Jeffrey J., MD Bush, Errol L., MD Husain, Aatif H., MD Wolfe, Walter G., MD McCann, Richard L., MD |
description | Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach. |
doi_str_mv | 10.1016/j.athoracsur.2008.07.089 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69858468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003497508015932</els_id><sourcerecordid>69858468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</originalsourceid><addsrcrecordid>eNqNkc9q3DAQxkVpSLabvELRqTe7kizZcg8FN3-2hUAg2RByEoo8ymrrtTaSvZBbHqR9uTxJtd2FQE89DRp9833MbxDClOSU0PLzMtfDwgdt4hhyRojMSZUTWb9DEyoEy0om6vdoQggpMl5X4gh9iHGZnix9H6IjWpPU5nyCFq8vv65Bd_jOh659ffmN53-NncHnfesfg7aD6x-_4GuIYzdEfOeGBR4WgGc-AJ43M3wGG2cAM3wPOkTc2AECvs1vcnxx1uBmvQ5-o7tjdGB1F-FkX6fo9uJ8fvo9u7ya_ThtLjMjaDFkrdS2LHnNrKW14YXg1GgNhhNjpX2QjElCq1IWlWyZLS21hRTc6qqtgTBSFVP0aeebYp9GiINauWig63QPfoyqrKWQPBlMkdwJTfAxBrBqHdxKh2dFidpSVkv1RlltKStSqUQ5jX7cZ4wPK2jfBvdYk-DbTgBp042DoKJx0BtoXQAzqNa7_0n5-o-J6VzvjO5-wjPEpR9Dn0gqqiJTRN1sr709NkmERF2w4g-ce6hl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69858468</pqid></control><display><type>article</type><title>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Hughes, G. Chad, MD ; Daneshmand, Mani A., MD ; Swaminathan, Madhav, MD ; Nienaber, Jeffrey J., MD ; Bush, Errol L., MD ; Husain, Aatif H., MD ; Wolfe, Walter G., MD ; McCann, Richard L., MD</creator><creatorcontrib>Hughes, G. Chad, MD ; Daneshmand, Mani A., MD ; Swaminathan, Madhav, MD ; Nienaber, Jeffrey J., MD ; Bush, Errol L., MD ; Husain, Aatif H., MD ; Wolfe, Walter G., MD ; McCann, Richard L., MD</creatorcontrib><description>Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/j.athoracsur.2008.07.089</identifier><identifier>PMID: 19049744</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Aneurysm, Dissecting - surgery ; Aorta, Thoracic - diagnostic imaging ; Aorta, Thoracic - surgery ; Aortic Aneurysm, Thoracic - mortality ; Aortic Aneurysm, Thoracic - surgery ; Blood Vessel Prosthesis - adverse effects ; Cardiothoracic Surgery ; Female ; Follow-Up Studies ; Humans ; Image Processing, Computer-Assisted ; Male ; Middle Aged ; Paraparesis - etiology ; Polytetrafluoroethylene ; Prosthesis Design - instrumentation ; Reoperation ; Stroke - etiology ; Surgery ; Survival Rate ; Tomography, X-Ray Computed ; Treatment Outcome ; United States ; United States Food and Drug Administration</subject><ispartof>The Annals of thoracic surgery, 2008-11, Vol.86 (5), p.1530-1538</ispartof><rights>The Society of Thoracic Surgeons</rights><rights>2008 The Society of Thoracic Surgeons</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</citedby><cites>FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19049744$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hughes, G. Chad, MD</creatorcontrib><creatorcontrib>Daneshmand, Mani A., MD</creatorcontrib><creatorcontrib>Swaminathan, Madhav, MD</creatorcontrib><creatorcontrib>Nienaber, Jeffrey J., MD</creatorcontrib><creatorcontrib>Bush, Errol L., MD</creatorcontrib><creatorcontrib>Husain, Aatif H., MD</creatorcontrib><creatorcontrib>Wolfe, Walter G., MD</creatorcontrib><creatorcontrib>McCann, Richard L., MD</creatorcontrib><title>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aneurysm, Dissecting - surgery</subject><subject>Aorta, Thoracic - diagnostic imaging</subject><subject>Aorta, Thoracic - surgery</subject><subject>Aortic Aneurysm, Thoracic - mortality</subject><subject>Aortic Aneurysm, Thoracic - surgery</subject><subject>Blood Vessel Prosthesis - adverse effects</subject><subject>Cardiothoracic Surgery</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Image Processing, Computer-Assisted</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Paraparesis - etiology</subject><subject>Polytetrafluoroethylene</subject><subject>Prosthesis Design - instrumentation</subject><subject>Reoperation</subject><subject>Stroke - etiology</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Tomography, X-Ray Computed</subject><subject>Treatment Outcome</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9q3DAQxkVpSLabvELRqTe7kizZcg8FN3-2hUAg2RByEoo8ymrrtTaSvZBbHqR9uTxJtd2FQE89DRp9833MbxDClOSU0PLzMtfDwgdt4hhyRojMSZUTWb9DEyoEy0om6vdoQggpMl5X4gh9iHGZnix9H6IjWpPU5nyCFq8vv65Bd_jOh659ffmN53-NncHnfesfg7aD6x-_4GuIYzdEfOeGBR4WgGc-AJ43M3wGG2cAM3wPOkTc2AECvs1vcnxx1uBmvQ5-o7tjdGB1F-FkX6fo9uJ8fvo9u7ya_ThtLjMjaDFkrdS2LHnNrKW14YXg1GgNhhNjpX2QjElCq1IWlWyZLS21hRTc6qqtgTBSFVP0aeebYp9GiINauWig63QPfoyqrKWQPBlMkdwJTfAxBrBqHdxKh2dFidpSVkv1RlltKStSqUQ5jX7cZ4wPK2jfBvdYk-DbTgBp042DoKJx0BtoXQAzqNa7_0n5-o-J6VzvjO5-wjPEpR9Dn0gqqiJTRN1sr709NkmERF2w4g-ce6hl</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>Hughes, G. Chad, MD</creator><creator>Daneshmand, Mani A., MD</creator><creator>Swaminathan, Madhav, MD</creator><creator>Nienaber, Jeffrey J., MD</creator><creator>Bush, Errol L., MD</creator><creator>Husain, Aatif H., MD</creator><creator>Wolfe, Walter G., MD</creator><creator>McCann, Richard L., MD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081101</creationdate><title>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</title><author>Hughes, G. Chad, MD ; Daneshmand, Mani A., MD ; Swaminathan, Madhav, MD ; Nienaber, Jeffrey J., MD ; Bush, Errol L., MD ; Husain, Aatif H., MD ; Wolfe, Walter G., MD ; McCann, Richard L., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-d8af66492ff19c43541caaec40cf8fb822801768378d2f6f1f3854fa7d9e02073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aneurysm, Dissecting - surgery</topic><topic>Aorta, Thoracic - diagnostic imaging</topic><topic>Aorta, Thoracic - surgery</topic><topic>Aortic Aneurysm, Thoracic - mortality</topic><topic>Aortic Aneurysm, Thoracic - surgery</topic><topic>Blood Vessel Prosthesis - adverse effects</topic><topic>Cardiothoracic Surgery</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Image Processing, Computer-Assisted</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Paraparesis - etiology</topic><topic>Polytetrafluoroethylene</topic><topic>Prosthesis Design - instrumentation</topic><topic>Reoperation</topic><topic>Stroke - etiology</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Tomography, X-Ray Computed</topic><topic>Treatment Outcome</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hughes, G. Chad, MD</creatorcontrib><creatorcontrib>Daneshmand, Mani A., MD</creatorcontrib><creatorcontrib>Swaminathan, Madhav, MD</creatorcontrib><creatorcontrib>Nienaber, Jeffrey J., MD</creatorcontrib><creatorcontrib>Bush, Errol L., MD</creatorcontrib><creatorcontrib>Husain, Aatif H., MD</creatorcontrib><creatorcontrib>Wolfe, Walter G., MD</creatorcontrib><creatorcontrib>McCann, Richard L., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hughes, G. Chad, MD</au><au>Daneshmand, Mani A., MD</au><au>Swaminathan, Madhav, MD</au><au>Nienaber, Jeffrey J., MD</au><au>Bush, Errol L., MD</au><au>Husain, Aatif H., MD</au><au>Wolfe, Walter G., MD</au><au>McCann, Richard L., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>“Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>86</volume><issue>5</issue><spage>1530</spage><epage>1538</epage><pages>1530-1538</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><abstract>Background The Gore TAG thoracic endoprosthesis (W. L. Gore and Associates, Flagstaff, AZ) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of thoracic aortic aneurysms on March 23, 2005, and remains the only FDA approved thoracic device to date. We present our experience with the TAG device for the 2 years post-approval to better characterize “real world” use and results outside the clinical trial setting. Methods Between March 23, 2005, and March 23, 2007, n = 91 thoracic endograft procedures were performed at our institution. Of these, n = 83 (91%) utilized the TAG device and form the basis of this report. Indications for endovascular repair were: fusiform or saccular aneurysm (n = 43; 52%), acute or chronic dissection (n = 30; 36%), acute or chronic traumatic transection (n = 7; 8%), and false aneurysm after prior aortic surgery (n = 3; 4%). A “hybrid” approach involving carotid-carotid bypass (n = 2), stage I elephant trunk procedure (n = 3), aortic arch debranching (n = 7), or complete visceral debranching (n = 5) was required in 20% of patients to create an adequate landing zone. Results Primary technical success rate was 98.8% (n = 82/83). Thirty-day rates of mortality and permanent stroke were both 3.6% (n = 3 each). Permanent paraparesis/paraplegia rate was 2.4% (n = 2). The 30-day rate of vascular or device-related complications requiring additional endovascular or open procedures was 7.2% (n = 6). During a mean duration of follow-up of 14 ± 8 months (range 0–28), there was one late death from aneurysm rupture (1.2%) and one late conversion to open repair (1.2%). Conclusions “Real world” utilization of the TAG device includes high rates of off-label use (nearly 50%) and “hybrid” techniques (20%) for the treatment of multiple pathologic entities of the thoracic and thoracoabdominal aorta. Regardless, short to mid-term results appear promising. Longer follow-up is needed to determine the durability of this approach.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>19049744</pmid><doi>10.1016/j.athoracsur.2008.07.089</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4975 |
ispartof | The Annals of thoracic surgery, 2008-11, Vol.86 (5), p.1530-1538 |
issn | 0003-4975 1552-6259 |
language | eng |
recordid | cdi_proquest_miscellaneous_69858468 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Adult Aged Aged, 80 and over Aneurysm, Dissecting - surgery Aorta, Thoracic - diagnostic imaging Aorta, Thoracic - surgery Aortic Aneurysm, Thoracic - mortality Aortic Aneurysm, Thoracic - surgery Blood Vessel Prosthesis - adverse effects Cardiothoracic Surgery Female Follow-Up Studies Humans Image Processing, Computer-Assisted Male Middle Aged Paraparesis - etiology Polytetrafluoroethylene Prosthesis Design - instrumentation Reoperation Stroke - etiology Surgery Survival Rate Tomography, X-Ray Computed Treatment Outcome United States United States Food and Drug Administration |
title | “Real World” Thoracic Endografting: Results With the Gore TAG Device 2 Years After U.S. FDA Approval |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T15%3A34%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%E2%80%9CReal%20World%E2%80%9D%20Thoracic%20Endografting:%20Results%20With%20the%20Gore%20TAG%20Device%202%20Years%20After%20U.S.%20FDA%20Approval&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=Hughes,%20G.%20Chad,%20MD&rft.date=2008-11-01&rft.volume=86&rft.issue=5&rft.spage=1530&rft.epage=1538&rft.pages=1530-1538&rft.issn=0003-4975&rft.eissn=1552-6259&rft_id=info:doi/10.1016/j.athoracsur.2008.07.089&rft_dat=%3Cproquest_cross%3E69858468%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69858468&rft_id=info:pmid/19049744&rft_els_id=S0003497508015932&rfr_iscdi=true |